<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article  PUBLIC "-//NLM//DTD Journal Publishing DTD v3.0 20080202//EN" "http://dtd.nlm.nih.gov/publishing/3.0/journalpublishing3.dtd"><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" dtd-version="3.0" xml:lang="en" article-type="research article"><front><journal-meta><journal-id journal-id-type="publisher-id">ACREM</journal-id><journal-title-group><journal-title>Asian Case Reports in Emergency Medicine</journal-title></journal-title-group><issn pub-type="epub">2328-0409</issn><publisher><publisher-name>Scientific Research Publishing</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="doi">10.12677/ACREM.2019.73003</article-id><article-id pub-id-type="publisher-id">ACREM-33334</article-id><article-categories><subj-group subj-group-type="heading"><subject>ACREM20190300000_63016390.pdf</subject></subj-group><subj-group subj-group-type="Discipline-v2"><subject>医药卫生</subject></subj-group></article-categories><title-group><article-title>
 
 
  托伐普坦联合托拉塞米治疗重症心力衰竭伴稀释性低钠血症的疗效及血液指标、心功能的影响观察
  Efficacy of Tolvaptan Combined with Torasemide in Severe Heart Failure Complicated by Dilute Hyponatremia and the Effects on Blood Parameters and Cardiac Function
 
</article-title></title-group><contrib-group><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>王</surname><given-names>宁</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>周</surname><given-names>志丽</given-names></name><xref ref-type="aff" rid="aff2"><sup>2</sup></xref><xref ref-type="aff" rid="aff1"><sup>1</sup></xref></contrib><contrib contrib-type="author" xlink:type="simple"><name name-style="western"><surname>杨</surname><given-names>蓉佳</given-names></name><xref ref-type="aff" rid="aff3"><sup>3</sup></xref><xref ref-type="corresp" rid="cor1"><sup>*</sup></xref></contrib></contrib-group><aff id="aff3"><addr-line>甘肃省人民医院急诊科，甘肃 兰州</addr-line></aff><aff id="aff2"><addr-line>甘肃省庆阳市人民医院急诊科，甘肃 庆阳 </addr-line></aff><aff id="aff1"><addr-line>null</addr-line></aff><pub-date pub-type="epub"><day>30</day><month>08</month><year>2019</year></pub-date><volume>07</volume><issue>03</issue><fpage>13</fpage><lpage>19</lpage><permissions><copyright-statement>&#169; Copyright  2014 by authors and Scientific Research Publishing Inc. </copyright-statement><copyright-year>2014</copyright-year><license><license-p>This work is licensed under the Creative Commons Attribution International License (CC BY). http://creativecommons.org/licenses/by/4.0/</license-p></license></permissions><abstract><p>
 
 
   目的：重症心力衰竭伴发稀释性低钠血症应用托伐普坦与托拉塞米联合治疗效果、心功能及血液指标分析。方法：选取2017年11月至2018年11月本院诊治120例重症心力衰竭伴发稀释性低钠血症患者，随机分两组，对照组予托拉塞米，研究组予托伐普坦与托拉塞米联合方案，分析两组患者临床疗效、心功能及血液指标情况。结果：(1) 对照组心力衰竭的治疗有效率是83.33%，较研究组的96.67%低，差异具统计学意义(P &lt; 0.05)；对照组稀释性低钠血症的临床有效率为85.00%，较研究组的96.67%低，差异具统计学意义(P &lt; 0.05)。(2) 治疗后，研究组LVESd (32.52 &#177; 3.49) mm、LVEDd (40.29 &#177; 4.31) mm比对照组低，LVEF (8.06 &#177; 6.52)%比对照组高(P &lt; 0.05)；研究组血钠(143.06 &#177; 2.23) mmol/L、血浆渗透压比对照组高，BNP比对照组低(P &lt; 0.05)。(3) 两组患者治疗前的生活质量评分对比，无统计学差异，P &gt; 0.05；但是经过治疗后两组的生活质量平均均较治疗前有显著提升，但是研究组患者提升的幅度显著高于对照组，差异显著，有统计学意义(P &lt; 0.05)。结论：重症心力衰竭伴发稀释性低钠血症应用托伐普坦与托拉塞米联合治疗，不仅能够改善患者的心功能指标水平和血液指标水平，而且还能大幅度提高患者的生活质量，进而获得满意的治疗效果，次疗法值得在临床中积极推广运用。 Objective: To observe the efficacy of Tolvaptan combined with Torsemide in the treatment of pa-tients with severe heart failure complicated by dilute hyponatremia, and its effects on cardiac function and blood parameters. Methods: A total of 120 patients with severe heart failure compli-cated by dilute hyponatremia who had received treatment in the Hospital between November 2017 and November 2018 were enrolled. They were randomly divided into two groups, with the control group given Torasemide and the study group given Tolvaptan combined with Torasemide. The clinical efficacy, cardiac function and blood parameters in the two groups were analyzed. Results: (1) The effective rate of treatment of heart failure in control group was 83.33%, which was lower than that of study group (96.67%). The difference was statistically significant (P &lt; 0.05). The clinical effective rate of dilute hyponatremia in the control group was 85.00%, which was lower than the study group’s 96.67%, and the difference was statistically significant (P &lt; 0.05). (2) After treatment, LVESd (32.52 &#177; 3.49) mm and LVEDd (40.29 &#177; 4.31) mm of the study group were lower than the control group, LVEF (8.06 &#177; 6.52)% was higher than the control group (P &lt; 0.05); the study group blood sodium (143.06 &#177; 2.23) mmol/L, plasma osmotic pressure was higher than that of the control group, and BNP was lower than the control group (P &lt; 0.05). (3) There was no significant difference in the quality of life scores between the two groups before treatment, P &gt; 0.05. However, the quality of life of the two groups was significantly higher than that before treatment, but the increase range of the patients in the study group was significantly higher than that of the control group. The difference was statistically significant (P &lt; 0.05). Conclusion: The combination of tolvaptan and torsemide in the treatment of severe heart failure with dilute hyponatremia can not only improve the level of heart function and blood levels, but also greatly improve the quality of life of patients. To obtain satisfactory therapeutic effects, secondary therapy is worthy of active promotion in clinical practice. 
 
</p></abstract><kwd-group><kwd>重症心力衰竭，稀释性低钠血症，托伐普坦，托拉塞米，疗效，心功能，血液指标, Severe Heart Failure</kwd><kwd> Dilute Hyponatremia</kwd><kwd> Tolvaptan</kwd><kwd> Torasemide</kwd><kwd> Efficacy</kwd><kwd> Cardiac Function</kwd><kwd> Blood Index</kwd></kwd-group></article-meta></front><body><sec id="s1"><title>托伐普坦联合托拉塞米治疗重症心力衰竭 伴稀释性低钠血症的疗效及血液指标、 心功能的影响观察<sup> </sup></title><p>王宁<sup>1</sup>，周志丽<sup>1</sup>，杨蓉佳<sup>2*</sup></p><p><sup>1</sup>甘肃省庆阳市人民医院急诊科，甘肃 庆阳</p><p><sup>2</sup>甘肃省人民医院急诊科，甘肃 兰州</p><disp-formula id="hanspub.33334-formula6"><graphic xlink:href="//html.hanspub.org/file/1-2440069x5_hanspub.png"  xlink:type="simple"/></disp-formula><p>收稿日期：2019年8月9日；录用日期：2019年8月23日；发布日期：2019年8月30日</p><disp-formula id="hanspub.33334-formula7"><graphic xlink:href="//html.hanspub.org/file/1-2440069x6_hanspub.png"  xlink:type="simple"/></disp-formula></sec><sec id="s2"><title>摘 要</title><p>目的：重症心力衰竭伴发稀释性低钠血症应用托伐普坦与托拉塞米联合治疗效果、心功能及血液指标分析。方法：选取2017年11月至2018年11月本院诊治120例重症心力衰竭伴发稀释性低钠血症患者，随机分两组，对照组予托拉塞米，研究组予托伐普坦与托拉塞米联合方案，分析两组患者临床疗效、心功能及血液指标情况。结果：(1) 对照组心力衰竭的治疗有效率是83.33%，较研究组的96.67%低，差异具统计学意义(P &lt; 0.05)；对照组稀释性低钠血症的临床有效率为85.00%，较研究组的96.67%低，差异具统计学意义(P &lt; 0.05)。(2) 治疗后，研究组LVESd (32.52 &#177; 3.49) mm、LVEDd (40.29 &#177; 4.31) mm比对照组低，LVEF (8.06 &#177; 6.52)%比对照组高(P &lt; 0.05)；研究组血钠(143.06 &#177; 2.23) mmol/L、血浆渗透压比对照组高，BNP比对照组低(P &lt; 0.05)。(3) 两组患者治疗前的生活质量评分对比，无统计学差异，P &gt; 0.05；但是经过治疗后两组的生活质量平均均较治疗前有显著提升，但是研究组患者提升的幅度显著高于对照组，差异显著，有统计学意义(P &lt; 0.05)。结论：重症心力衰竭伴发稀释性低钠血症应用托伐普坦与托拉塞米联合治疗，不仅能够改善患者的心功能指标水平和血液指标水平，而且还能大幅度提高患者的生活质量，进而获得满意的治疗效果，次疗法值得在临床中积极推广运用。</p><p>关键词 :重症心力衰竭，稀释性低钠血症，托伐普坦，托拉塞米，疗效，心功能，血液指标</p><disp-formula id="hanspub.33334-formula8"><graphic xlink:href="//html.hanspub.org/file/1-2440069x7_hanspub.png"  xlink:type="simple"/></disp-formula><p>Copyright &#169; 2019 by author(s) and Hans Publishers Inc.</p><p>This work is licensed under the Creative Commons Attribution International License (CC BY).</p><p>http://creativecommons.org/licenses/by/4.0/</p><p><img src="//html.hanspub.org/file/1-2440069x8_hanspub.png" /> <img src="//html.hanspub.org/file/1-2440069x9_hanspub.png" /></p></sec><sec id="s3"><title>1. 引言</title><p>在心内科临床中，心力衰竭属于较为严重的一种病症，主要是指适量的静脉回流下，因心肌收缩、舒张功能出现障碍，心排血量不能维持机体组织代谢的需求，引发循环功能相关障碍综合征 [<xref ref-type="bibr" rid="hanspub.33334-ref1">1</xref>]。相关研究发现，心力衰竭常见病因为心血管疾病等造成的心肌损害，或机体心脏的负荷过重导致心力衰竭，常见诱发因素包括体力过度消耗、感染、心律失常、情绪激动等造成发病 [<xref ref-type="bibr" rid="hanspub.33334-ref2">2</xref>]。心力衰竭患者的病情较为严重，需及时救治，否则病情持续进展后容易引发其他病症，加重病情，威胁患者的生命安全。当患者静息状态发生呼吸困难情况即是重症心力衰竭，稀释性低钠血症就是重症心力衰竭患者最常见的一种并发症，同时也导致心力衰竭患者死亡的重要原因之一。针对上述疾病患者，临床通常采用利尿剂方案治疗，但是很难有效缓解患者的稀释性低钠血症，不仅降低了患者的正常生活质量甚至威胁健康 [<xref ref-type="bibr" rid="hanspub.33334-ref3">3</xref>]。为提高该病患者的治疗疗效，本研究对2017年11月至2018年11月60例重症心力衰竭伴发稀释性低钠血症患者应用托伐普坦与托拉塞米联合效果分析，报告如下。</p></sec><sec id="s4"><title>2. 资料与方法</title><sec id="s4_1"><title>2.1. 一般资料</title><p>选取2017年11月至2018年11月本院诊治120例重症心力衰竭伴发稀释性低钠血症患者，均符合《中国心力衰竭诊断和治疗指南2014》。签署知情同意书，研究符合医学伦理会批准，确诊为重症心力衰竭伴发稀释性低钠血症；排除药物过敏者，精神心理病，严重肝肾病，恶性肿瘤者，2月内心脏手术者，合并其他疾病者，低血压者，资料不完整者，中途退出者。按照随机数字表分两组，每组60例，对照组男36例，女性24例，年龄56~86岁，平均(68.14 &#177; 11.37)岁，并高血压23例，并糖尿病11例，NYHA分级III级35例，IV级25例；研究组男35例，女性25例，年龄57~85岁，平均(67.23 &#177; 10.18)岁，并高血压37例，并糖尿病23例，NYHA分级III级34例，IV级26例。两组性别、年龄等基线资料无差异(P &gt; 0.05)。</p></sec><sec id="s4_2"><title>2.2. 治疗方法</title><p>两组患者均予以血管紧张素相关转换酶的抑制剂、醛固酮相关受体阻滞等常规对症药物，对照组在此基础上予托拉塞米(国药准字H200552495，南京正科医药股份有限公司)口服，每次10 mg，每天早晨一次，用药一周；研究组在对照组基础上予托伐普坦(国药准字H20110115，浙江大冢制药有限公司)口服联合方案，每次15 mg，每天1次，用药一周。</p></sec><sec id="s4_3"><title>2.3. 观察指标心功能指标</title><p>应用实时超声评价LVESd (左心室收缩的末期内径)、LVEDd (左心室舒张的末期内径)及LVEF (左心室的射血分数)；血液指标：血浆渗透压、血钾、血钠及脑钠肽(BNP) [<xref ref-type="bibr" rid="hanspub.33334-ref4">4</xref>] [<xref ref-type="bibr" rid="hanspub.33334-ref5">5</xref>]。治疗前后的生活质量参照QOL评分标准进行评估，分值范围是0~100分，分值越高说明患者的生活质量越高 [<xref ref-type="bibr" rid="hanspub.33334-ref6">6</xref>]。</p></sec><sec id="s4_4"><title>2.4. 疗效评价</title><p>(1) 心力衰竭的治疗疗效判定标准：经治疗，患者的临床症状基本消失或者完全消失，心功能分级较治疗前提升 ≥ 2级，视作治疗有效。经治疗，患者的临床症状较治疗前有明显减轻，心功能分级较治疗前提高1级，视作治疗好转。经治疗，患者的临床症状无任何变化或者加重，心功能分级较治疗前变化，或者患者死亡，视作治疗无效。(2) 稀释性低钠血症的治疗效果评估标准：治疗后患者无水肿为有效；经治疗患者有可见指凹性水肿，水肿范围已经较治疗前明显缩小，视作治疗好转；经治疗，可见指凹性水肿，并且水肿的范围加重或者扩大，视作治疗无效 [<xref ref-type="bibr" rid="hanspub.33334-ref7">7</xref>] [<xref ref-type="bibr" rid="hanspub.33334-ref8">8</xref>] [<xref ref-type="bibr" rid="hanspub.33334-ref9">9</xref>]。</p></sec><sec id="s4_5"><title>2.5. 统计学分析</title><p>数据应用SPSS 20.0统计包处理，计量数据以( x &#175; &#177; s )表示，用t检验，计数数据以(n)表示，用X<sup>2</sup>检验，当P &lt; 0.05时比较差异具有统计意义。</p></sec></sec><sec id="s5"><title>3. 结果</title><sec id="s5_1"><title>3.1. 两组临床疗效</title><sec id="s5_1_1"><title>3.1.1. 两组患者心力衰竭的治疗疗效对比</title><p>经过治疗后，对照组治疗有效20例、治疗好转30例、治疗无效10例，心力衰竭的临床有效率是83.33%；研究组治疗有效38例、治疗好转20例、治疗无效2例，心力衰竭的临床有效率是96.67%，研究组显著高于对照组，差异具统计学意义(P &lt; 0.05，X<sup>2</sup> = 5.9259)。</p></sec><sec id="s5_1_2"><title>3.1.2. 两组患者稀释性低钠血症的治疗疗效对比</title><p>经过治疗后，对照组治疗有效21例、治疗好转30例、治疗无效9例，稀释性低钠血症的临床有效率为85.00%；研究组治疗有效40例、治疗好转18例、治疗无效2例，稀释性低钠血症的临床有效率为96.67%，研究组显著高于对照组，差异具统计学意义(P &lt; 0.05，X<sup>2</sup> = 4.9041)。</p></sec></sec><sec id="s5_2"><title>3.2. 两组心功能指标</title><p>治疗后，研究组LVESd、LVEDd比对照组低，LVEF比对照组高(P &lt; 0.05)，见表1。</p><table-wrap id="table1" ><label><xref ref-type="table" rid="table1">Table 1</xref></label><caption><title> Two groups of cardiac function indicators ( x &#175; &#177; s , n = 60</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >LVESd (mm)</th><th align="center" valign="middle" >LVEDd (mm)</th><th align="center" valign="middle" >LVEF (%)</th></tr></thead><tr><td align="center" valign="middle" >研究组</td><td align="center" valign="middle" >32.52 &#177; 3.49</td><td align="center" valign="middle" >40.29 &#177; 4.31</td><td align="center" valign="middle" >48.06 &#177; 6.52</td></tr><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >43.21 &#177; 5.16</td><td align="center" valign="middle" >53.18 &#177; 5.29</td><td align="center" valign="middle" >37.15 &#177; 5.34</td></tr><tr><td align="center" valign="middle" >t</td><td align="center" valign="middle" >13.2925</td><td align="center" valign="middle" >14.6326</td><td align="center" valign="middle" >10.0275</td></tr><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle" >&lt;0.05</td><td align="center" valign="middle" >&lt;0.05</td><td align="center" valign="middle" >&lt;0.05</td></tr></tbody></table></table-wrap><p>表1. 两组心功能指标( x &#175; &#177; s , n = 60)</p><p>注：与对照组比较P &lt; 0.05。</p></sec><sec id="s5_3"><title>3.3. 两组血液指标</title><p>治疗后，两组血钾无明显差异，研究组血钠、血浆渗透压比对照组高，BNP比对照组低(P &lt; 0.05)，见表2。</p><table-wrap id="table2" ><label><xref ref-type="table" rid="table2">Table 2</xref></label><caption><title> Blood indicators of two groups ( x &#175; &#177; s , n = 60</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >血钠(mmol/L)</th><th align="center" valign="middle" >血钾(mmol/L)</th><th align="center" valign="middle" >血浆渗透压(mOsm∙kg<sup>−1</sup>∙H<sub>2</sub>O<sup>−1</sup>)</th><th align="center" valign="middle" >BNP (ng/L)</th></tr></thead><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >132.06 &#177; 3.68</td><td align="center" valign="middle" >4.18 &#177; 0.32</td><td align="center" valign="middle" >267.56 &#177; 60.74</td><td align="center" valign="middle" >1984.26 &#177; 215.41</td></tr><tr><td align="center" valign="middle" >研究组</td><td align="center" valign="middle" >143.06 &#177; 2.23<sup>a</sup></td><td align="center" valign="middle" >4.15 &#177; 0.46</td><td align="center" valign="middle" >321.03 &#177; 58.46<sup>a</sup></td><td align="center" valign="middle" >1212.52 &#177; 261.29<sup>a</sup></td></tr><tr><td align="center" valign="middle" >t</td><td align="center" valign="middle" >19.8017</td><td align="center" valign="middle" >0.4147</td><td align="center" valign="middle" >4.9130</td><td align="center" valign="middle" >17.6528</td></tr><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle" >&lt;0.05</td><td align="center" valign="middle" >&gt;0.05</td><td align="center" valign="middle" >&lt;0.05</td><td align="center" valign="middle" >&lt;0.05</td></tr></tbody></table></table-wrap><p>表2. 两组血液指标( x &#175; &#177; s , n = 60)</p><p>注：与对照组比较<sup>a</sup>P &lt; 0.05。</p></sec><sec id="s5_4"><title>3.4. 两组患者治疗前后的生活质量评分</title><p>两组患者治疗前的生活质量评分对比，无统计学差异，P &gt; 0.05；但是经过治疗后两组的平均生活质量较治疗前均有显著提升，但是研究组患者提升的幅度显著高于对照组，差异显著，有统计学意义(P &lt; 0.05)，见表3。</p><table-wrap id="table3" ><label><xref ref-type="table" rid="table3">Table 3</xref></label><caption><title> Quality of life scores before and after treatment in the two groups of patients ( x &#175; &#177; s , score</title></caption><table><tbody><thead><tr><th align="center" valign="middle" >组别</th><th align="center" valign="middle" >例数</th><th align="center" valign="middle" >治疗前</th><th align="center" valign="middle" >治疗后</th></tr></thead><tr><td align="center" valign="middle" >对照组</td><td align="center" valign="middle" >60</td><td align="center" valign="middle" >67.56 &#177; 5.66</td><td align="center" valign="middle" >80.47 &#177; 7.02<sup>b</sup></td></tr><tr><td align="center" valign="middle" >研究组</td><td align="center" valign="middle" >60</td><td align="center" valign="middle" >67.50 &#177; 5.68</td><td align="center" valign="middle" >88.65 &#177; 6.00<sup>ab</sup></td></tr><tr><td align="center" valign="middle" >t</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >0.0579</td><td align="center" valign="middle" >6.8612</td></tr><tr><td align="center" valign="middle" >P</td><td align="center" valign="middle" >-</td><td align="center" valign="middle" >0.9539</td><td align="center" valign="middle" >0.0000</td></tr></tbody></table></table-wrap><p>表3. 两组患者治疗前后的生活质量评分( x &#175; &#177; s ，分)</p><p>注：与对照组比较<sup>a</sup>P &lt; 0.05，与治疗前比，<sup>b</sup>P &lt; 0.05。</p></sec></sec><sec id="s6"><title>4. 讨论</title><p>心力衰竭(heart failure，简称：心衰)不是独立疾病，属于心脏病发展终末阶段，且大部分自左心衰开始 [<xref ref-type="bibr" rid="hanspub.33334-ref10">10</xref>]。重症心力衰竭临床主要表现是呼吸困难、活动受限、体液潴留等，且容易出现稀释性低钠血症 [<xref ref-type="bibr" rid="hanspub.33334-ref11">11</xref>]。临床通常用于利尿剂药物方案治疗，包括托拉塞米、有呋塞米等，但会出现不良反应，效果不甚理想 [<xref ref-type="bibr" rid="hanspub.33334-ref12">12</xref>] [<xref ref-type="bibr" rid="hanspub.33334-ref13">13</xref>]。分析其原因，主要是因为利尿剂虽然可以帮助心力衰竭患者及时排除体内多余的水分，及时降低患者心脏的前负荷，同时阻碍患者机体中的钾离子、钠离子以及氯离子的转运体，但是如果大量使用该类药物治疗，可能会导致患者体内的钠离子过度排毒，反而会引起低钠血症，加重病情 [<xref ref-type="bibr" rid="hanspub.33334-ref14">14</xref>] [<xref ref-type="bibr" rid="hanspub.33334-ref15">15</xref>] [<xref ref-type="bibr" rid="hanspub.33334-ref16">16</xref>]。因此，寻找一种安全且有效的临床治疗手段显得十分关键。</p><p>本次研究中，对2017年11月至2018年11月本院诊治120例重症心力衰竭伴发稀释性低钠血症患者实施详细的分组，并施予不同方法进行治疗后，对照组心力衰竭的治疗有效率是83.33%，较研究组的96.67%低，差异具统计学意义；对照组稀释性低钠血症的临床有效率为85.00%，较研究组的96.67%低，差异具统计学意义，由此可见，采取托伐普坦与托拉塞米联合用药方案，可以显著提高重症心力衰竭伴稀释性低钠血症患者的临床治疗效果，此外，研究结果还提示治疗后，研究组LVESd、LVEDd比对照组低，LVEF比对照组高；治疗后，两组血钾无明显差异，研究组血钠、血浆渗透压比对照组高，BNP比对照组低；结果与白晓黎 [<xref ref-type="bibr" rid="hanspub.33334-ref17">17</xref>] 的研究结果相符合。不仅如此，经过治疗后两组的生活质量平均均较治疗前有显著提升，但是研究组患者提升的幅度显著高于对照组，差异显著，有统计学意义。进一步说明采取托伐普坦与托拉塞米联合用药方案，可以大幅发改善重症心衰伴稀释性低钠血症患者的心功能以及血液指标，促进患者生活质量不断提高，这对于提升患者的整体治疗效果有重要意义 [<xref ref-type="bibr" rid="hanspub.33334-ref18">18</xref>] [<xref ref-type="bibr" rid="hanspub.33334-ref19">19</xref>] [<xref ref-type="bibr" rid="hanspub.33334-ref20">20</xref>]。分析其原因，可能是因为患者口服托拉塞米之后，药物效果直接作用于髓袢升支粗段，通过对髓质部、皮质Cl重吸收抑制利尿，通过可对机体髓袢升支粗段Na、Cl主动的重吸收进行阻断，发挥利尿、排钠效果。</p><p>其次，托拉塞米的适应症较广，耐受性比较好，花费少，利尿作用快、强且持久，患者不良反应少，属于高效类利尿剂。托伐普坦能降低肾脏对于水重吸收，促排水而改善机体心脏负荷；其可用于治疗明显高容量、正常容量低钠血症，能缓解顽固水肿等临床症状，且不会出现血压降低、肝肾功能受损等 [<xref ref-type="bibr" rid="hanspub.33334-ref21">21</xref>] [<xref ref-type="bibr" rid="hanspub.33334-ref22">22</xref>] [<xref ref-type="bibr" rid="hanspub.33334-ref23">23</xref>] [<xref ref-type="bibr" rid="hanspub.33334-ref24">24</xref>]。本研究组联合用药方案治疗的结果进一步证实其效果相比单用托拉塞米更为显著。值得注意的是，本次研究纳入的样本量较少，可能对研究结果的精准性造成一定影响，建议后期增加样本，再进一步探索联合用药方案的远期效果。</p><p>综上所述，重症心力衰竭伴发稀释性低钠血症应用托伐普坦与托拉塞米联合，能有效改善心功能与血液相关指标情况，效果显著，具一定临床应用与研究价值。</p></sec><sec id="s7"><title>文章引用</title><p>王 宁,周志丽,杨蓉佳. 托伐普坦联合托拉塞米治疗重症心力衰竭伴稀释性低钠血症的疗效及血液指标、心功能的影响观察Efficacy of Tolvaptan Combined with Torasemide in Severe Heart Failure Complicated by Dilute Hyponatremia and the Effects on Blood Parameters and Cardiac Function[J]. 亚洲急诊医学病例研究, 2019, 07(03): 13-19. https://doi.org/10.12677/ACREM.2019.73003</p></sec><sec id="s8"><title>参考文献</title></sec></body><back><ref-list><title>References</title><ref id="hanspub.33334-ref1"><label>1</label><mixed-citation publication-type="other" xlink:type="simple">李军锋, 梁晶. 口服托伐普坦对急性失代偿性心力衰竭合并低钠血症的疗效及安全性研究[J]. 中国药物与临床, 2019, 19(8): 1349-1350.</mixed-citation></ref><ref id="hanspub.33334-ref2"><label>2</label><mixed-citation publication-type="other" xlink:type="simple">胡武明, 施振华, 叶士勇, 等. 托伐普坦片治疗心力衰竭伴收缩功能障碍的临床研究[J]. 中国临床药理学杂志, 2019, 35(7): 617-619.</mixed-citation></ref><ref id="hanspub.33334-ref3"><label>3</label><mixed-citation publication-type="other" xlink:type="simple">王立立, 韩爽, 张至, 等. 不同剂量托伐普坦治疗老年慢性心力衰竭伴利尿剂抵抗患者的疗效与安全性观察[J]. 中华老年心脑血管病杂志, 2019, 21(4): 375-378.</mixed-citation></ref><ref id="hanspub.33334-ref4"><label>4</label><mixed-citation publication-type="other" xlink:type="simple">Kaneko, H., Hoelschermann, F., Tambor, G., et al. (2019) Impact of N-Terminal Pro-B-Type Natriu-retic Peptide Response on Long-Term Prognosis after Transcatheter Aortic Valve Implantation for Severe Aortic Stenosis and Heart Failure. Heart and Vessels, 34, 536-543. &lt;br&gt;https://doi.org/10.1007/s00380-018-1297-z</mixed-citation></ref><ref id="hanspub.33334-ref5"><label>5</label><mixed-citation publication-type="other" xlink:type="simple">王毅, 杨征. 托伐普坦和沙库巴曲缬沙坦钠片对慢性心力衰竭患者心功能及血清钠水平的影响研究[J]. 陕西医学杂志, 2019, 48(4): 470-472.</mixed-citation></ref><ref id="hanspub.33334-ref6"><label>6</label><mixed-citation publication-type="other" xlink:type="simple">孟珠. 慢性心力衰竭患者呼吸困难、抑郁情绪与生活质量的关系[D]: [硕士学位论文]. 济南: 山东大学, 2012.</mixed-citation></ref><ref id="hanspub.33334-ref7"><label>7</label><mixed-citation publication-type="other" xlink:type="simple">Schmidt, T. and Frerker, C. (2019) Treatment Challenges in Patients with Acute Heart Failure and Severe Aortic Valve Stenosis. Current Cardiology Reports, 21, 1-8. &lt;br&gt;https://doi.org/10.1007/s11886-019-1135-7</mixed-citation></ref><ref id="hanspub.33334-ref8"><label>8</label><mixed-citation publication-type="other" xlink:type="simple">Vikmane, M., Kalējs, O., Kamzola, G., et al. (2018) Assessment of Cardiac Resynchronisation Therapy Efficacy Determining Factors for Patients with Moderate and Severe Heart Failure in the Population of Latvia in a 12 and 24 Month Study. Proceedings of the Latvian Academy of Sciences. Section B. Natural, Exact, and Applied Sciences, 72, 313-321. &lt;br&gt;https://doi.org/10.2478/prolas-2018-0049</mixed-citation></ref><ref id="hanspub.33334-ref9"><label>9</label><mixed-citation publication-type="other" xlink:type="simple">李柏林, 邹育明, 梁明俊, 等. 重组人脑利钠肽联合托伐普坦治疗青中年急性心肌梗死合并心力衰竭的临床观察[J]. 广东医科大学学报, 2018, 36(6): 660-663.</mixed-citation></ref><ref id="hanspub.33334-ref10"><label>10</label><mixed-citation publication-type="other" xlink:type="simple">Kanwar, M., Khoo, C., Lohmueller, L., et al. (2019) Predicting Post LVAD Acute Severe Right Heart Failure Using Bayesian Analysis. Journal of Heart and Lung Transplantation, 38, S357-S357. &lt;br&gt;https://doi.org/10.1016/j.healun.2019.01.907</mixed-citation></ref><ref id="hanspub.33334-ref11"><label>11</label><mixed-citation publication-type="other" xlink:type="simple">庞国珍, 黄志敏, 陈伟婵, 等. 托伐普坦联合常规治疗慢性心力衰竭(CHF)并低钠血症的效果分析[J]. 齐齐哈尔医学院学报, 2018, 39(23): 2753-2755.</mixed-citation></ref><ref id="hanspub.33334-ref12"><label>12</label><mixed-citation publication-type="other" xlink:type="simple">Mateescu, A.D., Călin, A., Beladan, C.C., et al. (2019) Left Atrial Dysfunction as an Independent Correlate of Heart Failure Symptoms in Patients with Severe Aortic Stenosis and Preserved Left Ventricular Ejection Fraction. Journal of the American Society of Echocardiography, 32, 257-266. &lt;br&gt;https://doi.org/10.1016/j.echo.2018.11.007</mixed-citation></ref><ref id="hanspub.33334-ref13"><label>13</label><mixed-citation publication-type="other" xlink:type="simple">Orea-Tejeda, A., Navarrete-Peñaloza, A.G., Verdeja-Vendrell, L., et al. (2018) Right Heart Failure as a Risk Factor for Severe Exacerbation in Patients with Chronic Obstructive Pulmonary Disease: Prospective Cohort Study. The Clinical Respiratory Journal, 12, 2635-2641. &lt;br&gt;https://doi.org/10.1111/crj.12969</mixed-citation></ref><ref id="hanspub.33334-ref14"><label>14</label><mixed-citation publication-type="other" xlink:type="simple">Kuang, H., Zhou, X., Li, L., Yi, Q.J., et al. (2018) Early Severe Coronary Heart Disease and Ischemic Heart Failure in Homozygous Familial Hypercholesterolemia: A Case Report. Medicine, 97, e12869.&lt;br&gt;https://doi.org/10.1097/MD.0000000000012869</mixed-citation></ref><ref id="hanspub.33334-ref15"><label>15</label><mixed-citation publication-type="other" xlink:type="simple">王茜, 杨小东, 刘东霞, 等. 托伐普坦与托拉塞米治疗重症心力衰竭伴稀释性低钠血症的效果比较[J]. 河北医药, 2018, 40(23): 3582-3585.</mixed-citation></ref><ref id="hanspub.33334-ref16"><label>16</label><mixed-citation publication-type="other" xlink:type="simple">李广. 托伐普坦与托拉塞米治疗慢性心衰急性发作的临床效果观察[J]. 名医, 2018(11): 214.</mixed-citation></ref><ref id="hanspub.33334-ref17"><label>17</label><mixed-citation publication-type="other" xlink:type="simple">白晓黎. 托伐普坦与托拉塞米对慢性心衰急性发作的治疗效果对比研究[J]. 首都食品与医药, 2018, 25(18): 50.</mixed-citation></ref><ref id="hanspub.33334-ref18"><label>18</label><mixed-citation publication-type="other" xlink:type="simple">隋利军, 李维, 甘建祥, 等. 托伐普坦对慢性心力衰竭急性发作合并利尿剂抵抗的疗效研究[J]. 国际心血管病杂志, 2018, 45(3): 186-188.</mixed-citation></ref><ref id="hanspub.33334-ref19"><label>19</label><mixed-citation publication-type="other" xlink:type="simple">刘婷, 孙爱梅, 陈还珍. 托伐普坦联合托拉塞米治疗老年心力衰竭的短期疗效[J]. 中华临床医师杂志(电子版), 2017, 11(21): 2357-2361.</mixed-citation></ref><ref id="hanspub.33334-ref20"><label>20</label><mixed-citation publication-type="other" xlink:type="simple">杨小东, 王茜, 刘东霞, 等. 托伐普坦与托拉塞米治疗重症心力衰竭伴稀释性低钠血症的疗效分析[J]. 河北医药, 2018, 40(21): 3303-3305+3309.</mixed-citation></ref><ref id="hanspub.33334-ref21"><label>21</label><mixed-citation publication-type="other" xlink:type="simple">张丽, 陈伟. 托伐普坦与托拉塞米在慢性心力衰竭急性发作患者中的疗效对比[J]. 中国循证心血管医学杂志, 2017, 9(10): 1182-1184.</mixed-citation></ref><ref id="hanspub.33334-ref22"><label>22</label><mixed-citation publication-type="other" xlink:type="simple">贺仙光. 托伐普坦联合托拉塞米治疗老年难治性心衰的疗效观察[J]. 中国社区医师, 2017, 33(24): 39+41.</mixed-citation></ref><ref id="hanspub.33334-ref23"><label>23</label><mixed-citation publication-type="other" xlink:type="simple">陈曦, 解珍, 姜妤, 等. 托伐普坦与托拉塞米治疗重症心力衰竭伴稀释性低钠血症临床疗效的对比研究[J]. 实用心脑肺血管病杂志, 2017, 25(4): 67-69.</mixed-citation></ref><ref id="hanspub.33334-ref24"><label>24</label><mixed-citation publication-type="other" xlink:type="simple">胡玲玲, 任江华. 托伐普坦与托拉塞米治疗慢性心衰急性发作的疗效比较[J]. 西南国防医药, 2017, 27(4): 338-340.</mixed-citation></ref></ref-list></back></article>